WuXi NextCODE Becomes the First and Only CAP, CLIA, and California Accredited Sequencing Laboratory in China

Highest quality certified genomics facility is uniquely positioned to deliver precision medicine

Feb 23, 2016, 07:00 ET from WuXi NextCODE

SHANGHAI and CAMBRIDGE, Mass. and REYKJAVIK, Iceland, Feb. 23, 2016 /PRNewswire/ -- WuXi NextCODE, the global genomic information and precision medicine company, today announced that its Shanghai sequencing facility has been accredited by the College of American Pathologists (CAP) and become the first such laboratory in China to be licensed by the State of California, enabling it to process samples from California. WuXi NextCODE is also the only sequencing facility in China with CLIA (Clinial Laboratory Improvement Amendments) certification from the US Centers for Medicare and Medicaid (CMS).

"We are a natively global enterprise serving laboratories, hospitals, companies, governments and patients on four continents," said Hannes Smarason, COO of WuXi NextCODE, a subsidiary of WuXi AppTec. "Our system is the emerging global standard for querying, storing and collaborating with genomic data, and our global cloud solution similarly leverages our partner DNAnexus' HIPAA-compliant security. The CAP, CLIA and California accreditation of our sequencing lab demonstrates the same leading standards, enabling us to provide products and services to more customers and to the most demanding standards in every market."

"We offer the global gold standard in next generation sequencing through our Shanghai laboratory," said Dr Hongye Sun, chief technology officer and head of China operations and business at WuXi NextCODE. "These latest accreditations underscore that quality and our commitment to meet the exacting standards and regulatory requirements of our clinical and research clients and partners, in China and worldwide."

About WuXi NextCODE 
WuXi NextCODE is a genomic information company applying sequence data to deliver better health and precision medicine for people around the world. Our uniquely comprehensive open-access capabilities include CLIA- and CAP-certified sequencing; a novel database architecture that mines and manages more genomes than any other; the world's leading genome interpretation and discovery system, available installed or in the cloud; a pioneering internet of DNA that enables users to query and collaborate using massive genomic datasets online with unrivalled resolution and efficiency; the know-how to apply genomics to optimize drug discovery and development; and a growing range of tests and scans to improve rare disease diagnosis, targeted cancer treatment, and wellness. With offices in Shanghai, Cambridge, Massachusetts and Reykjavik, we serve companies and health systems, clinicians and researchers, and people and populations worldwide. WuXi NextCODE is a subsidiary of WuXi AppTec, the open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States.

Contact:
Edward Farmer
VP, Communications & New Ventures
WuXi NextCODE
efarmer@wuxinextcode.com 
+1 781 775 6206

Logo - http://photos.prnewswire.com/prnh/20151006/274295LOGO

SOURCE WuXi NextCODE



RELATED LINKS

http://www.nextcode.com